Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
Status:
RECRUITING
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.